MLYS
Mineralys Therapeutics, Inc.·Healthcare
30.58
0.065%(+0.02)
Market ClosedLast Updated: — ET
52W L: $12.5952W H: $47.65
MLYS NEWS
defenseworld.net
3d ago
David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider David Malcom Rodman sold 2,170 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $27.38, for a total value of $59,414.60. Following the sale, the insider directly owned 76,140 shares in the company, valued at
fool.com
Apr 7
Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?
CEO Jon Congleton sold 75,000 shares for a total transaction value of ~$1.97 million on April 2, 2026. The sale represented 9.61% of direct holdings prior to the transaction, reducing direct ownership to 705,051 shares.
defenseworld.net
Apr 3
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares
Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) CEO Jon Congleton sold 75,000 shares of the company's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $26.27, for a total transaction of $1,970,250.00. Following the sale, the chief executive officer owned 705,051 shares of the company's stock,
globenewswire.com
Mar 24
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A.
seekingalpha.com
Mar 12
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 12
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
